United States Government Publishing Office publisher pbl distributor dst United States National Archives and Records Administration Office of the Federal Register author aut Government Organization text government publication eng FR Regulatory Information 2013_register executive 2013-08-27 article Notices D09002ee1c7fb1232 D09002ee1c7fb12cc United States Department of Health and Human Services originator org United States Government Agency or Subagency United States National Institutes of Health originator org United States Government Agency or Subagency This notice, in accordance with 35 U.S.C. 209 and 37 CFR part 404, that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to Antares Pharma Inc., a company having a place of business in Ewing, New Jersey, to practice the inventions embodied in the following patent applications and patents: 1. U.S. Patent Application 11/137,114, filed May 25, 2005, titled "Scopolamine for the Treatment of Depression and Anxiety" [HHS Ref. No. E-175-2004/0-US-01]; 2. European Patent 1896025, issued December 28, 2011, titled "Scopolamine for the Treatment of Depression and Anxiety" [HHS Ref. No. E-175-2004/0-EP-03]; 3. German Patent 1896025, issued December 28, 2011, titled "Scopolamine for the Treatment of Depression and Anxiety" [HHS Ref. No. E-175-2004/0-DE-07]; 4. French Patent 1896025, issued December 28, 2011, titled "Scopolamine for the Treatment of Depression and Anxiety" [HHS Ref. No. E-175-2004/0-FR-08]; 5. British Patent 1896025, issued December 28, 2011, titled "Scopolamine for the Treatment of Depression and Anxiety" [HHS Ref. No. E-175-2004/0-GB-09]; and 6. Canadian Patent Application 2610025, filed May 18, 2006, titled "Scopolamine for the Treatment of Depression and Anxiety" [HHS Ref. No. E-175-2004/0-CA-04. The patent rights in these inventions have been assigned to the Government of the United States of America. The territory of the prospective Exclusive Patent License may be worldwide, and the field of use may be limited to: "The use of scopolamine for treatment of depression, including major depressive disorder, wherein the route of administration is subcutaneous, intramuscular, or transdermal delivery such as through injection or a patch or topical gel-based product". This announcement is the second notice to grant an exclusive license to this technology. 78 FR 52939 https://www.govinfo.gov/app/details/FR-2013-08-27/2013-20880 2013-20880 fr27au13-72 4140-01-P https://www.govinfo.gov/app/details/FR-2013-08-27/2013-20880 https://www.govinfo.gov/content/pkg/FR-2013-08-27/html/2013-20880.htm https://www.govinfo.gov/content/pkg/FR-2013-08-27/pdf/2013-20880.pdf 1 p. 52939 52939 78 FR 52939 Prospective Grant of Exclusive Patent License: Use of Scopolamine to Treat Depression; Federal Register Vol. 78, Issue NOTICE 2013-20880 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health 2013-09-26 4140-01-P 2013-20880 Notice.

This notice, in accordance with 35 U.S.C. 209 and 37 CFR part 404, that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to Antares Pharma Inc., a company having a place of business in Ewing, New Jersey, to practice the inventions embodied in the following patent applications and patents: 1. U.S. Patent Application 11/137,114, filed May 25, 2005, titled "Scopolamine for the Treatment of Depression and Anxiety" [HHS Ref. No. E-175-2004/0-US-01]; 2. European Patent 1896025, issued December 28, 2011, titled "Scopolamine for the Treatment of Depression and Anxiety" [HHS Ref. No. E-175-2004/0-EP-03]; 3. German Patent 1896025, issued December 28, 2011, titled "Scopolamine for the Treatment of Depression and Anxiety" [HHS Ref. No. E-175-2004/0-DE-07]; 4. French Patent 1896025, issued December 28, 2011, titled "Scopolamine for the Treatment of Depression and Anxiety" [HHS Ref. No. E-175-2004/0-FR-08]; 5. British Patent 1896025, issued December 28, 2011, titled "Scopolamine for the Treatment of Depression and Anxiety" [HHS Ref. No. E-175-2004/0-GB-09]; and 6. Canadian Patent Application 2610025, filed May 18, 2006, titled "Scopolamine for the Treatment of Depression and Anxiety" [HHS Ref. No. E-175-2004/0-CA-04. The patent rights in these inventions have been assigned to the Government of the United States of America. The territory of the prospective Exclusive Patent License may be worldwide, and the field of use may be limited to: "The use of scopolamine for treatment of depression, including major depressive disorder, wherein the route of administration is subcutaneous, intramuscular, or transdermal delivery such as through injection or a patch or topical gel-based product". This announcement is the second notice to grant an exclusive license to this technology.

Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before September 26, 2013 will be considered. Prospective Grant of Exclusive Patent Licenses: Use of Scopolamine to Treat Depression , tongb@mail.nih.gov Vol. 78, no. 166 Office of the Federal Register, National Archives and Records Administration 2013-08-27 continuing daily deposited born digital 200 p. Table of Contents: AE 2.7: GS 4.107: AE 2.106: KF70.A2 https://www.govinfo.gov/app/details/FR-2013-08-27 P0b002ee186073330 0097-6326 0042-1219 0364-1406 769-004-00000-9 000582072 f:fr27au13 https://www.govinfo.gov/app/details/FR-2013-08-27 https://www.govinfo.gov/content/pkg/FR-2013-08-27/pdf/FR-2013-08-27.pdf https://www.govinfo.gov/content/pkg/FR-2013-08-27/xml/FR-2013-08-27.xml fdlp 52827 53015 DGPO 2013-08-27 2024-06-03 FR-2013-08-27 machine generated eng FR FR-2013-08-27 78 166